Dr. Bonifant is studying how best to direct the immune system to combat acute myeloid leukemia (AML), a blood cancer of both children and adults. By specifically directing T immune cells to AML, she hopes to make therapy stronger and more effective, while also reducing toxicity. She is exploring the activity of T cells targeting multiple AML-specific antigens that do not affect normal cells. The ultimate goal of the work is to develop new strategies to treat AML.
Damon Runyon Researchers
Meet Our Scientists
Challice L. Bonifant, MD, PhD
Project title: "Dual-antigen targeting by ENG-T cells as improved anti-AML therapy"
Institution: The Johns Hopkins University School of Medicine
Award Program: Sohn Fellow
Sponsor(s) / Mentor(s): Donald Small, MD, PhD
Cancer Type: Blood, Pediatric, All Cancers
Research Area: Immunotherapy
